A PILOT-STUDY OF NEDAPLATIN AND ETOPOSIDE FOR RECURRENT GYNECOLOGICALMALIGNANCIES

Nedaplatin is a new analogue of cisplatin with similar efficacy but le ss renal toxicity. We assessed the efficacy and toxicity of nedaplatin and etoposide for recurrent gynecological malignancies. Eight patient s were treated with 100 mg/m(2) of nedaplatin (day 1) and 70 mg/m(2) o f etoposide (days 1, 3, and 5) every 4 weeks. A total of 17 courses wa s given. Grade 3/4 leucopenia and thrombocytopenia occurred, but was m anageable. The response rate was 37.5% (partial response n=3; no chang e n=4; progressive disease n=1). In conclusion, a phase II study of th is regimen for recurrent gynecological malignancies is warranted.